FrancophonIA/ELRC3.0 huggingface dataset:
English: [EMA/MB/146523/2011] The Management Board noted the report on performance of national competent authorities with respect to a subset of KPIs, which had been agreed by the Board in June 2010.
Maltese: [EMA/MB/146523/2011] Il-Bord ta' Tmexxija ħa nota tar-rapport dwar il-prestazzjoni tal-awtoritajiet nazzjonali kompetenti fir-rigward ta' subsett ta' KPIs, li kien intlaħaq qbil dwaru mill-Bord f'Ġunju 2010.
English: EMA/MB/232704/2011 Management Board
Maltese: EMA/MB/728591/2011 Il-Bord ta' Tmexxija
English: • impact of health-technology assessment on the work of regulators, presented by Kent Woods, of the Medicines and Healthcare products Regulatory Agency (MHRA).
Maltese: Kent Woods, tal-Aġenzija Regolatorja tal-Mediċini u l-prodotti tal-Kura tas-Saħħa (MHRA).
English: Mediator
Maltese: Medjatur
English: Republic, finalised on 3 January 2011.
Maltese: iffinalizzata fit-3 ta' Jannar 2011.
English: [EMA/MB/808316/2010] The Management Board noted the minutes adopted by written procedure on 7 February 2011.
Maltese: [EMA/MB/808316/2010] Il-Bord ta' Tmexxija ħa nota tal-minuti li ġew adottati permezz tal-proċedura bil-miktub fis-7 ta' Frar 2011.
English: [EMA/MB/757388/2011] The Board adopted the amendments to the implementing rules on the Agency's fees.
Maltese: [EMA/MB/757388/2011] Il-Bord adotta l-emendi fir-regoli implimentattivi dwar il-ħlasijiet tal-Aġenzija.
English: The Board discussion focused on the implementation of the new legislative provisions in relation to EudraVigilance and EU Telematics Controlled Terms.
Maltese: Id-diskussjoni tal-Bord iffokat fuq l-implimentazzjoni tad-dispożizzjonijiet leġiżlattivi ġodda fir-rigward tal-EudraViġilanza u t-Termini Kkontrollati tat-Telematika tal-UE.
English: • [EMA/MB/105462/2011] Outcome of written procedures during the period from 17 October 2010 to
Maltese: • [EMA/MB/105462/2011] L-eżitu tal-proċeduri bil-miktub matul il-perjodu mis-17 ta' Ottubru 2010
English: • No 02/2011 - the appointment of Miloslav SALAVEC as CHMP alternate, proposed by the Czech
Maltese: • Nru 02/2011 - il-ħatra ta' Miloslav SALAVEC bħala membru supplenti tas-CHMP, proposta mir
English: finalised on 20 December 2010.
Maltese: Rumanija, iffinalizzata fl-20 ta' Diċembru 2010.
English: • The revision of the clinical trials legislation (target for the proposal is the second quarter of 2012).
Maltese: • Ir-reviżjoni tal-leġiżlazzjoni dwar il-provi kliniċi (il-mira għall-proposta hija t-tieni kwart tal-2012).
English: The Board also supported the proposals for maintaining the EudraVigilance system until the new functionalities are implemented (in relation to data-quality management, support of EVDAS and the revised implementation of the EudraVigilance Access Policy).
Maltese: Il-Bord appoġġa wkoll il-proposti għaż-żamma tas-sistema tal-EudraViġilanza sakemm jiġu implimentati l-funzjonalitajiet ġodda (fir-rigward tal-ġestjoni tal-kwalità tad-dejta, lappoġġ tal-EVDAS u l-implimentazzjoni riveduta tal-Politika ta' Aċċess tal-EudraViġilanza).
English: The members noted the update report from the Heads of Medicines Agencies on a range of topics, including the following:
Maltese: Il-membri ħadu nota tar-rapport ta' aġġornament mill-Kapijiet tal-Aġenziji tal-Mediċini fuq firxa ta' suġġetti, inklużi dawn li ġejjin:
English: The full annual report will be submitted to the Board in May 2011 for adoption at the June 2011 meeting.
Maltese: Ir-rapport annwali sħiħ sejjer jintbagħat lill-Bord f'Mejju 2011 sabiex jiġi adottat fil-laqgħa ta' Ġunju 2011.
English: Minutes of the 70th meeting of the Management Board
Maltese: Minuti tas-70 laqgħa tal-Bord ta' Tmexxija
English: Currently, the Agency provides annual reports drawn up by the internal audit capability and by the Audit Advisory Committee (AAC), as well as final reports from the European Court of Auditors, with the Agency's replies.
Maltese: Attwalment, l-Aġenzija qiegħda tipprovdi rapporti annwali mħejjija mill-kapaċità tal-verifika interna u mill-Kumitat Konsultattiv tal-Verifika (AAC), kif ukoll rapporti finali mill-Qorti Ewropea tal-Awdituri, bit-tweġibiet tal-Aġenzija.
English: • The task force on the availability of medicines, which has completed its mandate.
Maltese: • It-task force fuq id-disponibbiltà tal-mediċini, li kkompletat il-mandat tagħha.
English: In this context, reference was made to the joint HMA/EMA training strategy.
Maltese: F'dan il-kuntest, saret referenza għall-istrateġija konġunta ta' taħriġ tal-HMA/EMA.
English: • The process for the implementation of the strategy paper (the HMA meetings will be reorganised to facilitate the implementation of the strategy paper).
Maltese: • Il-proċess għall-implimentazzjoni tad-dokument ta' strateġija (il-laqgħat tal-HMA ser jiġu organizzati mill-ġdid sabiex tiġi ffaċilitata l-implimentazzjoni tad-dokument ta' strateġija).
English: In adopting its decision, the Board imposed a set of limitations on these and any future activities for a period of two years after leaving the Agency, including prohibitions on taking managerial and executive positions in the pharmaceutical industry, and on providing product-related advice with regard to activities falling within the remit of the Agency.
Maltese: Fl-adozzjoni tad-deċiżjoni tiegħu, il-Bord impona sett ta' limitazzjonijiet fuq dawn l-attivitajiet u kull attività futura għal perjodu ta' sentejn wara t-tluq mill-Aġenzija, inklużi projbizzjonijiet fuq it-teħid ta' pożizzjonijiet maniġerjali u eżekuttivi fl-industrija farmaċewtika, u fuq l-għoti ta' pariri relatati malprodotti fir-rigward ta' attivitajiet li jaqgħu fi ħdan il-mandat tal-Aġenzija.
English: The discussion was held behind closed doors and focused on two areas of potential conflict of interests: firstly, whether any activity risked the misuse of confidential or privileged information gained during his leadership of the Agency; and secondly, whether any activity risked improper influence on decisions taken by the Agency.
Maltese: Id-diskussjoni saret wara l-bibien magħluqa u iffokat fuq żewġ oqsma ta' kunflitt ta' interessi potenzjali: l-ewwel nett, jekk kwalunkwe attività rriskjatx l-użu ħażin ta' informazzjoni kunfidenzjali jew privileġġata miksuba matul it-tmexxija tiegħu tal-Aġenzija; u t-tieni nett, jekk kwalunkwe attività rriskjatx l-influwenza mhux xierqa fuq id-deċiżjonijiet meħuda mill-Aġenzija.
English: Members regretted the late notification by Mr Lönngren of details of his activities.
Maltese: Il-membri ddispjaċihom għan-notifika tard mis-Sur Lönngren tad-dettalji tal-attivitajiet tiegħu.
English: The Board was informed that the Director-General for DG SANCO has written to remind the Agency that audit reports need to be provided to the Board.
Maltese: Il-Bord kien informat li d-Direttur Ġenerali għad-DĠ SANCO kiteb biex ifakkar lill-Aġenzija li jeħtieġ li jiġu pprovduti rapporti ta' verifika lill-Bord.
English: Amendments to the delegate reimbursement rules
Maltese: Emendi għar-regoli ddelegati dwar ir-rimborż
English: [EMA/MB/149825/2011] The Board adopted the amendments to the delegate reimbursement rules which allow flight tickets to be changed if a meeting ends two hours earlier or later than planned.
Maltese: [EMA/MB/149825/2011] Il-Bord adotta l-emendi għar-regoli ddelegati dwar ir-rimborż li jippermettu li l-biljetti tat-titjiriet jinbidlu jekk laqgħa tintemm sagħtejn qabel jew aktar tard milli ppjanat.
English: • The Mediator case (a stress test was conducted in the context of the new pharmacovigilance legislation).
Maltese: • Il-każ tal-Medjatur (sar test tal-istress fil-kuntest tal-leġiżlazzjoni ġdida dwar il-farmakoviġilanza).
English: Republic, finalised on 4 February 2011.
Maltese: Repubblika Ċeka, iffinalizzata fl-4 ta' Frar 2011.
English: The Management Board adopted the preliminary work programme and the preliminary draft budget 2012.
Maltese: Il-Bord ta' Tmexxija adotta l-programm ta' ħidma preliminari u l-abbozz preliminari tal-baġit 2012.
English: • The next cycle of the Benchmarking of the European Medicines Agencies (BEMA) exercise (the BEMA cycle will follow the five-year period of the HMA strategy and the EMA road map).
Maltese: • Il-proċedura għall-ħatra tad-Direttur Eżekuttiv (il-laqgħa tal-Bord tal-5 ta' Mejju 2011 sejra tinżamm kif ippjanat).
English: The Board also discussed that the training programme for regulators is an important element to ensure that high-quality assessors are available.
Maltese: Il-Bord iddiskuta wkoll li l-programm ta' taħriġ għar-regolaturi huwa element importanti sabiex ikun żgurat li hemm evalwaturi ta' kwalità għolja disponibbli.
English: • [EMA/MB/66833/2011] Performance of the Agency's scientific procedures: Survey 2010 for medicinal products for human use.
Maltese: • [EMA/MB/66833/2011] Il-prestazzjoni tal-proċeduri xjentifiċi tal-Aġenzija:
English: Update from the meeting of Chairs of the EU agencies
Maltese: Aġġornament mil-laqgħa tal-Presidenti tal-aġenziji tal-UE
English: The two-day meeting of the Management Board of the European Medicines Agency (EMA) started on 16 March 2011 with presentations and an exchange of views on the following topics:
Maltese: Il-laqgħa ta' jumejn tal-Bord ta' Tmexxija tal-Aġenzija Ewropea tal-Mediċini (EMA) bdiet fis-16 ta' Marzu 2011 bi preżentazzjonijiet u skambju ta' fehmiet dwar is-suġġetti li ġejjin:
English: Methadone is a synthetic opioid.
Maltese: Methadone huwa opjojdi sintetiku.
English: The review of oral methadone medicines containing povidone started on 10 April 2014 under Article 107i of Directive 2001/83/EC.
Maltese: Ir-reviżjoni tal-mediċini orali tal-methadone li fihom povidon bdiet fl10 ta' April 2014 skont l-Artikolu 107i tad-Direttiva 2001/83/KE.
English: It was also noted that misuse by injection of methadone product is an inherent risk in the target population with evidence showing an occurrence of injection of methadone for oral use among injecting drug users varying from 5.0% to 79.5% (Winstock et al. 2010, Guichard et al. 2003, Waldvogel et al 2005, Judson G et al. 2010, and Vlahov D et al. 2007) and an underreporting considered to be likely.
Maltese: Ġie nnotat ukoll li l-użu ħażin permezz ta' injezzjoni ta' prodott tal-methadone huwa riskju inerenti fil-popolazzjoni fil-mira b'evidenza turi okkorrenza tal-injezzjoni ta' methadone għall-użu orali fost persuni li jinjettaw id-droga li tvarja minn 5.0% għal 79.5% (Winstock et al. 2010, Guichard et al. 2003, Waldvogel et al 2005, Judson G et al. 2010, u Vlahov D et al. 2007) u n-nuqqas ta' rappurtar huwa meqjus bħala probabbli.
English: Following parenteral administration, it is generally accepted that low molecular weight povidone (Mw <25 000) is readily excreted by the kidney: the glomerulus can excrete within a few days all povidone of Mw 40 000 or below; the normal glomerulus of healthy human subjects is relatively impermeable to povidone Mw >70 000 (while in humans with nephrotic disease, the permeability for larger molecules was increased); the reticuloendothelial system (RES) retains molecules with a Mw >110,000 (Ravin et al. 1952; Hulme and Hardwicke 1968).
Maltese: Wara l-għoti parenterali, huwa ġeneralment aċċettat li povidon b'piż molekulari baxx (Mw <25 000) jiġi faċilment eliminat mill-kliewi: fi ftit jiem il-glomerulus jista' jelimina l-povidon kollu ta' anqas minn Mw 40 000; il-glomerulus normali ta' individwi umani b'saħħithom huwa relattivament impermeabbli għal povidon Mw >70 000 (waqt li fil-bnedmin b'mard nefrotiku, il-permeabilità għal molekuli kbar żdiedet); is-sistema retikuloendoteljali (RES) iżżomm molekuli b'Mw >110,000 (Ravin et al. 1952; Hulme u Hardwicke 1968).
English: Povidone is an excipient available in a variety of different molecular sizes from K12 (low molecular weight (Mw), average Mw ~ 2000) to K90 (high Mw, average Mw 1,100,000).
Maltese: K12 (piż molekulari baxx (Mw), medju Mw ~ 2000) għal K90 (Mw għoli, Mw medju 1,100,000).
English: Methadone tablets containing low Mw povidone (K25 or K30)
Maltese: Pilloli ta' methadone li fihom Mw baxx (K25 jew K30)
English: Methadone oral solution containing high molecular weight povidone (K90)
Maltese: Soluzzjoni orali ta' methadone li fiha povidon b'piż molekulari għoli (K90)
English: The review took into account 15 cases of serious adverse reactions reported in Norway.
Maltese: Ir-reviżjoni qieset 15-il każ ta' reazzjonijiet avversi serji rrapportati fin-Norveġja.
English: The overall effectiveness of methadone maintenance treatment is established in the literature and has been reviewed in several articles.
Maltese: L-effikaċja ġenerali tal-kura ta' manteniment b'methadone hija stabbilita fil-letteratura u ġiet riveduta f'diversi artikoli.
English: There is evidence that lower molecular weight povidone (<25,000) is readily excreted but that higher Mw povidone (>110,000) is not, or (>70,000) only partially excreted;
Maltese: Hemm evidenza li povidon b'piż molekulari aktar baxx (<25,000) jiġi faċilment eliminat iżda li povidon b'Mw ogħla (>110,000) mhuwiex, jew (>70,000) jiġi parzjalment eliminat;
English: Treatment with methadone should be given in the context of a wider rehabilitation program, opioid substitution therapy (OST).
Maltese: Ilkura b'methadone għandha tingħata fil-kuntest ta' programm usa' ta' riabilitazzjoni, terapija ta' sostituzzjoni bl-opjojdi (OST).
English: • The PRAC considered the procedure under Article 107i of Directive 2001/83/EC, for methadone medicinal products for oral use containing povidone.
Maltese: • Il-PRAC ikkunsidra l-proċedura skont l-Artikolu 107i tad-Direttiva 2001/83/KE, għall-prodotti mediċinali tal-methadone għall-użu orali li fihom povidon.
English: The cases concerned former or current injecting drug abusers, aged 24 to 53 years old.
Maltese: Il-każijiet kienu jittrattaw persuni li qabel kienu jew li attwalment jinjettaw id-droga, b'etajiet ivarjaw minn 24 sa 53 sena.
English: • The PRAC considered case reports, including fatal cases, in former or current injecting drug users, and noted the serious adverse reactions, the nature of which (including bone marrow adverse effects and pathological fractures) was consistent with the accumulation of povidone and also noted that povidone deposition in organs and tissues had been seen on biopsies.
Maltese: • Il-PRAC qies rapporti ta' każijiet, inklużi każijiet fatali, f'persuni li preċedentement jew attwalment jinjettaw id-droga, u nnota r-reazzjonijiet avversi serji, li n-natura tagħhom (inklużi effetti avversi tal-mudullun u ksur patoloġiku) kienet konsistenti mal-akkumulazzjoni ta' povidon u nnota wkoll li fuq bijopsiji kienet dehret depożizzjoni ta' povidon fl-organi u t-tessuti.
English: The PRAC noted that all these 15 cases reported “intentional drug misuse”, “product deposit” and “drug administered via inappropriate route” and were assessed by the regional pharmacovigilance centre in Norway as possibly or probably related to the injection of povidone.
Maltese: Il-PRAC innota li dawn il-15-il każ kollha irrapportaw “użu ħażin intenzjonat tal-mediċina”, “depożitu talprodott” u “mediċina mgħotija permezz ta' rotta mhux adegwata” u ġew ivvalutati miċ-ċentru reġjonali ta' farmakoviġilanza fin-Norveġja bħala possibbilment jew probabbilment relatati mal-injezzjoni ta' povidon.
English: • The PRAC noted that high molecular weight povidone was present only in one methadone oral solution dosed at 2 mg/ml, which contains povidone K90 with an average molecular weight of 1,100,000.
Maltese: • Il-PRAC innota li povidon b'piż molekulari għoli kien preżenti biss f'soluzzjoni orali waħda ta' methadone f'doża ta' 2 mg/ml, li fiha povidon K90 b'piż molekulari medju ta' 1,100,000.
English: Flexible-dose methadone maintenance therapy is more clinically effective than no drug therapy in dependent opioid users.
Maltese: Terapija ta' manteniment b'dożi flessibbli ta' methadone hija klinikament aktar effikaċi minn terapija mingħajr ebda bil-mediċini f'utenti dipendenti fuq l-opjojdi.
English: It is mainly used in oral solutions (K90) as a viscosity-increasing agent, or as a binding agent (e.g. K25, K30) in tablets.
Maltese: Jintuża prinċipalment f'soluzzjonijiet orali (K90) bħala aġent li jżid il-viskożità, jew bħala aġent li jgħaqqad (eż. K25, K30) filpilloli.
English: The inclusion of povidone K90 in oral methadone solutions was initially intended to enhance viscosity and reduce the risk of misuse by injection.
Maltese: L-inklużjoni ta' povidon K90 f'soluzzjonijiet orali ta' methadone inizjalment kienet maħsuba biex iżżid ilviskożità u tnaqqas ir-riskju ta' użu ħażin permezz ta' injezzjoni.
English: Other methadone products containing povidone concerned by the review are tablets and have lower Mw povidone (e.g. K25, K30, also in lower amount), which is known to be excreted from the kidney and therefore is expected not to be retained in the body.
Maltese: Prodotti oħra tal-methadone li fihom povidon ikkonċernati mir-reviżjoni huma l-pilloli u għandhom povidon b'Mw aktar baxx (eż. K25, K30, anke f'ammont aktar baxx), li huwa magħruf li jiġi eliminat mill-kliewi u għalhekk huwa mistenni li ma jinżammx fil-ġisem.
English: On 2nd April 2014, the Norwegian Medicines Agency, NOMA, triggered a referral under Article 107i of Directive 2001/83/EC concerning methadone-containing medicines for oral use containing povidone asking the PRAC to review the benefit-risk balance of all oral methadone medicines containing polyvinylpyrrolidone (more commonly known as povidone or PVP) authorised in the EU and to make a recommendation to the Human Co-ordination Group for Mutual Recognition and Decentralised Procedures (CMDh) on any measures necessary to ensure the safe and effective use, and on whether the marketing authorisation for these products should be maintained, varied, suspended or withdrawn.
Maltese: Fit-2 ta' April 2014, l-Aġenzija Norveġiża tal-Mediċini, NOMA, tat bidu għal riferiment skont lArtikolu 107i tad-Direttiva 2001/83/KE fir-rigward ta' mediċini li fihom methadone għall-użu orali li fihom povidon fejn talbet lill-PRAC jirrevedi l-bilanċ tal-benefiċċju-riskju tal-mediċini orali kollha talmethadone li fihom polivinilpirrolidon (magħruf l-aktar bħala povidon jew PVP) awtorizzati fl-UE u biex jagħmel rakkomandazzjoni lill-Grupp ta ' Koordinazzjoni għall-Għarfien Reċiproku u l-Proċeduri.
English: High molecular weight povidone therefore accumulates if injected intravenously and povidone deposition in organs and tissues (in particular bone marrow and bone tissue) have been reported in the literature after substantial intravenous administration leading to ‘povidone storage disease' (Kepes et al. 1993; Kuo et al. 1997; Dunn et al. 1998; Huang et al. 2012).
Maltese: Għalhekk jekk jiġi injettat ġolvina povidon b'piż molekulari għoli jakkumula u d-depożizzjoni ta' povidon fl-organi u fit-tessuti (b'mod partikolari l-mudullun u tessut tal-għadam) kienet irrapportata fil-letteratura wara l-għoti sostanzjali ġol-vini li wassal għall-‘marda tal-ħżin ta' povidon' (Kepes et al. 1993; Kuo et al. 1997;
English: The CMDh, having considered the PRAC recommendation dated 23 July 2014 pursuant to Article 107k(1) and (2) of Directive 2001/83/EC, reached an agreement on the suspension of the marketing authorisations for methadone oral solution containing high molecular weight povidone (K90).
Maltese: Is-CMDh, wara li qies ir-rakkomandazzjoni tal-PRAC datata t-23 ta' Lulju 2014 skont l-Artikolu 107k(1) u (2) tad-Direttiva 2001/83/KE, laħaq ftehim dwar is-sospensjoni tal-awtorizzazzjonijiet għat-tqegħid fis-suq għas-soluzzjoni orali ta' methadone li fiha povidon b'piż molekulari għoli (K90).
English: • The PRAC was of the opinion that available pre-clinical and clinical data provide evidence that high molecular weight povidone (>110,000) when injected is likely to be permanently retained in the body, in particular in the bone marrow and bone tissue.
Maltese: • Il-PRAC kien tal-fehma li d-dejta preklinika u klinika disponibbli tipprovdi evidenza li meta povidon b'piż molekulari għoli (>110,000) jiġi injettat huwa probabbli li jinżamm b'mod permanenti filġisem, b'mod partikolari fil-mudullun u t-tessut tal-għadam.
English: The distribution and elimination of povidone when administered intravenously has been well investigated and studies using radioactive labelled povidone of different molecular weight have demonstrated that clearance of polymers after intravenous administration is dependent on molecular weight.
Maltese: Id-distribuzzjoni u l-eliminazzjoni ta' povidon meta jingħata ġol-vina ġew investigati sew u studji li użaw povidon radjuattiv ittikkettat b'piż molekulari differenti wrew li t-tneħħija tal-polimeri wara l-għoti ġolvina hija dipendenti fuq il-piż molekulari.
English: 2001/83/EC the benefit risk balance of methadone oral solutions containing povidone K90 is not favourable;
Maltese: • Abbażi tad-data disponibbli, il-PRAC ikkonkluda, li skont l-Artikolu 116 tad-Direttiva 2001/83/KE ilbilanċ tal-benefiċċju-riskju ta' soluzzjonijiet orali ta' methadone li fihom povidon K90 mhuwiex favorevoli;
English: Overall summary of the scientific evaluation of methadone products for oral use containing povidone
Maltese: Sommarju ġenerali tal-valutazzjoni xjentifika ta' prodotti tal-methadone għall-użu orali li fihom povidon
English: In the context of the review of methadone products containing povidone, the PRAC noted that high molecular weight povidone was present only in one methadone oral solution dosed at 2 mg/ml (containing high molecular weight povidone, K90).
Maltese: Fil-kuntest tar-reviżjoni tal-prodotti tal-methadone li fihom povidon, il-PRAC innota li povidon b'piż molekulari għoli kien preżenti biss f'soluzzjoni waħda ta' methadone orali f'doża ta' 2 mg/ml (li fiha 11.7 mg/ml ta' povidon b'piż molekulari għoli, K90).
English: • The PRAC noted that the risk of misuse by injection of methadone products for oral use is wellknown in the target population, evidence of which is available from the literature;
Maltese: • Il-PRAC innota li r-riskju ta' użu ħażin permezz tal-injezzjoni ta' prodotti tal-methadone għall-użu orali huwa magħruf sew fil-popolazzjoni fil-mira, u evidenza ta' dan hija disponibbli mill-letteratura;
English: For one of the five patients the bone marrow biopsy showed about 90% histiocytic infiltration characteristic for povidone deposit and only about 5% of bone marrow available for erythropoiesis.
Maltese: Għal wieħed millħames pazjenti l-bijopsija tal-mudullun uriet infiltrazzjoni istoċitika ta' madwar 90% karatteristika għal depożitu ta' povidon u madwar 5% biss tal-mudullun disponibbli għal eritropoesi.
English: Six kidney biopsies were presented and all demonstrated deposits of povidone in the tubular-interstitial area.
Maltese: Ġew ippreżentati sitt bijopsiji tal-kliewi u kollha urew depożiti ta' povidon fiż-żona tubulari interstizjali.
English: However, the causality of povidone deposits and bone marrow failure and skeletal fracture has been reasonably demonstrated, and the mechanism of pathophysiology appears to be related to the spatial competition of deposits and bone marrow (Kepes et al 1993; Kuo et al 1997; Dunn et al 1998; Huang et al 2012).
Maltese: Madankollu, il-kawżalità tad-depożiti ta' povidon u insuffiċjenza tal-mudullun u ksur skeletriku intweriet b'mod raġonevoli, u l-mekkaniżmu talpatofiżjoloġija jidher li huwa relatat mal-kompetizzjoni spazjali tad-depożiti u l-mudullun (Kepes et al 1993; Kuo et al 1997;